These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 3567092)

  • 1. The role of 1,25-dihydroxy-vitamin D3(1,25(OH)2D3) in the treatment of idiopathic myelofibrosis.
    Eugster C; Brun del Re GP; Bucher U
    Br J Haematol; 1987 Mar; 65(3):381. PubMed ID: 3567092
    [No Abstract]   [Full Text] [Related]  

  • 2. 1,25-Dihydroxy-vitamin D3 (1,25(OH)2D3) in the treatment of idiopathic myelofibrosis.
    Petrini M; Cecconi N; Azzara A; Ambrogi F; Grassi B
    Br J Haematol; 1986 Nov; 64(3):624-5. PubMed ID: 3790450
    [No Abstract]   [Full Text] [Related]  

  • 3. 1,25 Dihydroxy-vitamin D3 (1,25 (OH)2 vit D3) in the treatment of idiopathic myelofibrosis.
    Duncombe AS; Pearson TC; Nunan TO; Miller A; McCarthy DM
    Br J Haematol; 1987 Aug; 66(4):579-80. PubMed ID: 3663514
    [No Abstract]   [Full Text] [Related]  

  • 4. The usefulness of 1,25-dihydroxy-vitamin D3(1,25(OH)2vitD3) in the treatment of idiopathic myelofibrosis.
    Richard C; Mazorra F; Iriondo A; Mazo E; Bello C; Zubizarreta A
    Br J Haematol; 1986 Feb; 62(2):399-400. PubMed ID: 3753878
    [No Abstract]   [Full Text] [Related]  

  • 5. [Is 1,25(OH)2D3 effective in chronic osteomyelofibrosis?].
    Eugster C; Brun del Re GP; Bucher U
    Schweiz Med Wochenschr; 1986 Dec; 116(50):1767-70. PubMed ID: 3798067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 1-25 (OH)2 D3 in idiopathic myelofibrosis: a preliminary report.
    Petrini M; Cecconi N; Ambrogi F; Grassi B
    Haematologica; 1987; 72(6):567-9. PubMed ID: 3126118
    [No Abstract]   [Full Text] [Related]  

  • 7. 1,25-Dihydroxyvitamin D3 in the treatment of idiopathic thrombocythemia and myelofibrosis.
    Foa P; Maiolo AT; Cortellaro M; Ortolani S; Pogliani E; Deliliers GL; Iurlo A; Zocchi L; Gualdoni A; Polli E
    Haematologica; 1990; 75(3):294-5. PubMed ID: 2227630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 1,25-Dihydroxyvitamin D3 and myelofibrosis.
    McCarthy D; Hibbin J; Matutes E; Daniel P; Catovsky D; Goldman JM
    Lancet; 1984 Jun; 1(8389):1298. PubMed ID: 6145004
    [No Abstract]   [Full Text] [Related]  

  • 9. [Beneficial effect of 1,25-dihydroxyvitamin D3 in the treatment of myelofibrosis].
    Palomera L; García Díez I; Martínez R
    Med Clin (Barc); 1989 Sep; 93(7):265-8. PubMed ID: 2811498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 1 alpha-Hydroxyvitamin D3 in the treatment of primary myelofibrosis: in vitro effect of vitamin D3 metabolites on the bone marrow fibroblasts.
    Hyodo H; Kimura A; Nakata Y; Ohta H; Kuramoto A
    Int J Hematol; 1993 Apr; 57(2):131-7. PubMed ID: 8388271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A role for 1,25-dihydroxyvitamin D3 in control of bone-marrow collagen deposition?
    McCarthy DM; Hibbin JA; Goldman JM
    Lancet; 1984 Jan; 1(8368):78-80. PubMed ID: 6140427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myelofibrosis.
    Ozsoylu S
    Acta Haematol; 1995; 94(4):218. PubMed ID: 8610483
    [No Abstract]   [Full Text] [Related]  

  • 13. 1,25(OH)2D3 and 25-OHD3 in the treatment of renal osteodystrophy: comparison of combined versus 1,25(OH)2D3 administration alone.
    Coen G; Taccone Gallucci M; Bonucci E; Ballanti P; Bianchi AR; Bianchini G; Matteucci MC; Mazzaferro S; Picca S; Taggi F; Cinotti GA; Casciani CU
    Miner Electrolyte Metab; 1983; 9(1):19-27. PubMed ID: 6687749
    [No Abstract]   [Full Text] [Related]  

  • 14. Management of disturbed calcium metabolism in uraemic patients: 1. Use of vitamin D metabolites.
    Schömig M; Ritz E
    Nephrol Dial Transplant; 2000; 15 Suppl 5():18-24. PubMed ID: 11073270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The beneficial effect of 1,25-dihydroxycholecalciferol on the excess of blasts and the myelofibrosis in 2 cases of chronic myeloproliferative syndrome].
    Raya Sánchez JM; Hernández Nieto L; Brito Barroso ML; Hernández García MT
    Med Clin (Barc); 1994 Mar; 102(10):380-2. PubMed ID: 8182985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Growth inhibitory effects on human colon adenocarcinoma-derived Caco-2 cells and calcemic potential of 1 alpha,25-dihydroxyvitamin D3 analogs: structure-function relationships.
    Bischof MG; Redlich K; Schiller C; Chirayath MV; Uskokovic M; Peterlik M; Cross HS
    J Pharmacol Exp Ther; 1995 Dec; 275(3):1254-60. PubMed ID: 8531089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alterations in serum and urine parameters reflecting bone turnover in uremic patients during treatment with 1,25-dihydroxyvitamin D3 and 24,25-dihydroxyvitamin D3.
    Mortensen BM; Gordeladze JO; Lyngdal PT; Aarseth HP; Gautvik KM
    Miner Electrolyte Metab; 1993; 19(2):78-85. PubMed ID: 8377728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical evidence for 1,25-dihydroxycholecalciferol action in myelofibrosis.
    Arlet P; Nicodeme R; Adoue D; Larregain-Fournier D; Delsol G; le Tallec Y
    Lancet; 1984 May; 1(8384):1013-4. PubMed ID: 6143927
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical and laboratory studies of 1,25-dihydroxycholecalciferol in myelofibrosis.
    McKinley R; Kwan YL; Ford D; Lam-po-tang PR; Mason RS; Manoharan A
    Br J Haematol; 1987 Feb; 65(2):252-4. PubMed ID: 3828239
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.